Heterozygous or Homozygous Familial Hypercholesterolemia
Metabolic·MeSH: Homozygous Familial Hypercholesterolemia
Prevalence
0.5 / 100K
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| inclisiran | Novartis AG (NVS) |
Phase 4(1)
| Drug | Company |
|---|---|
| Inclisiran | Novartis AG (NVS) |
Frequently asked questions
How many drugs are in development for Heterozygous or Homozygous Familial Hypercholesterolemia?
BioSniper tracks 2 drugs in development for Heterozygous or Homozygous Familial Hypercholesterolemia across 1 company.
How many clinical trials target Heterozygous or Homozygous Familial Hypercholesterolemia?
There are 1 clinical trial targeting Heterozygous or Homozygous Familial Hypercholesterolemia tracked by BioSniper.
What is the prevalence of Heterozygous or Homozygous Familial Hypercholesterolemia?
The estimated prevalence of Heterozygous or Homozygous Familial Hypercholesterolemia is approximately 0.5 per 100,000 population.
Deep-dive into Heterozygous or Homozygous Familial Hypercholesterolemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis